Lilly's Retevmo Delivers Event-Free Survival Benefit As Adjuvant Therapy In Early-Stage Ret Fusion-Positive Lung Cancer

Reuters
Feb 16
Feb 16 (Reuters) - Eli Lilly and Co ::
*LILLY'S RETEVMO (SELPERCATINIB) DELIVERS SUBSTANTIAL EVENT-FREE SURVIVAL BENEFIT AS AN ADJUVANT THERAPY IN EARLY-STAGE RET FUSION-POSITIVE LUNG CANCER
*ELI LILLY - PHASE 3 LIBRETTO-432 STUDY MEETS PRIMARY ENDPOINT WITH IMPROVED EVENT-FREE SURVIVAL
*ELI LILLY - OVERALL SURVIVAL RESULTS TRENDED IN FAVOR OF SELPERCATINIB, BUT WERE IMMATURE AT TIME OF THIS ANALYSIS WITH FEW EVENTS OBSERVED
*Further company coverage: LLY.N

((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))
Source Date/Time = 16-FEB-202611:49:05 GMT

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10